Tempus AI secures $200 million five‑year extension of AstraZeneca oncology partnership
Tempus AI and AstraZeneca signed a fifth amendment to their master services agreement, extending the collaboration through December 31 20231. The amendment creates a five‑year financial commitment of $200 million, with AstraZeneca expected to pay $40 million each year but not less than $32 million annually. If the total amount is not reached, the term can be prolonged to cover the shortfall, and AstraZeneca remains liable for any unpaid balance if it ends the deal early.
Why it matters
The agreement guarantees Tempus AI a steady revenue stream of at least $32 million per year for the next five years, improving its cash flow outlook. Investors should note that the commitment may extend into a sixth year if the full $200 million is not met, potentially affecting timing of revenue recognition.
Key facts
- 1The amendment was executed on November 16 2026 and becomes effective January 1 2027. tipranks.com
- 2The partnership now runs through December 31 2031, with a possible extension to December 31 2032 if the $200 million commitment is not fulfilled. tipranks.com
- 3AstraZeneca committed to pay a total of $200 million over the five‑year period. tipranks.com
- 4The annual payment goal is $40 million, with a floor of $32 million each renewal year. tipranks.com
- 5If AstraZeneca terminates the agreement early, it must cover any unpaid portion of the $200 million commitment. tipranks.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.